Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program. The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.
open label, one group Purposive sampling of hospitalized children ≤14 years of age with confirmed IPD
Study Type
OBSERVATIONAL
Enrollment
457
There is no intervention. This is a non interventional study.
Agia Sophia Children's Hospital
Athens, Attica, Greece
University Hospital of Herakleion
Heraklion, Herakleion, Greece
Venizeleion General Hospital of Herakleion
Heraklion, Herakleion, Greece
The serotype distribution of invasive S. pneumoniae isolates of hospitalized children up to 14 years of age after the introduction of the 7-valent conjugate pneumococcal vaccine
Time frame: yearly
Serotype distribution of resistant S. pneumoniae isolates
Time frame: yearly
Serotype distribution of IPD between immunized and non immunized children ≤14 years of age
Time frame: yearly
Antimicrobial susceptibilities of IPD isolates and rates of resistance to penicillin
Time frame: yearly
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University Hospital of Ioannina
Ioannina, Ioannina, Greece
Ahepa Hospital Paediatric Outpatient Special Clinic 1st Kyri
Thessaloniki, Thessaloniki, Greece
Ippokrateion Peripheral Hospital of Thessaloniki
Thessaloniki, Thessaloniki, Greece
Peripheral Hospital of Trikala
Trikala, Trikala, Greece
University Hospital of Alexandroupolis
Alexandroupoli, Greece
University of Thessaly School of Medicine
Larissa, Greece